zoledronic acid

Computed tomography confirmed mixed calcifications (26×24 mm) with heterogeneous enhancement. Magnetic resonance imaging revealed an ovoid calcified soft-tissue mass within the soleus/paratibial region, marked surrounding edema, and mild periosteal reaction, supporting an intermediate-stage juxtacortical MO and making a primary bone tumor unlikely. Management included nonsteroidal anti-inflammatory drugs, ketoprofen, then indomethacin, zoledronic acid infusion, and physical therapy emphasizing pain-free mobilization and ultrasound therapy.

He was treated with intravenous fluids, zoledronic acid, and calcitonin with symptomatic improvement and was referred to a tertiary center for surgical evaluation...Instead, a broad differential should be maintained, including concurrent malignancy or inherited syndromes. Early recognition of overlapping etiologies is essential to prevent delayed diagnosis or missed malignancy in patients with persistent hypercalcemia.

P=N/A, N=188, Recruiting, Hebei Medical University Third Hospital; Hebei Medical University Third Hospital

P1, N=20, Recruiting, Children's Hospital Medical Center, Cincinnati

In conclusion, PBM modulated the response of SaOs-2 osteoblastic cells treated with ZA in a wavelength- and dose-dependent manner. PBM at 808 nm and 1 J stimulated cell metabolic activity and upregulated BCL-2 expression, suggesting a potential protective effect against ZA-induced cytotoxicity.

Zoledronate upregulates TLR4 expression in neutrophils and keratinocytes and augments LPS-induced inflammation, suggesting a mechanism by which BPs exacerbate oral inflammatory responses. These findings provide new insight into the pathogenesis of BRONJ and suggest that targeting TLR4 signaling may be a potential strategy to mitigate BP-associated oral complications.

P4, N=36, Not yet recruiting, Western Sydney Local Health District

Suppressing bone remodeling with zoledronate or targeting macrophage-associated niche factors mitigated clonal development. Collectively, our study reveals a previously unrecognized inflammatory landscape shaped by local bone remodeling. The finding presents targetable mechanisms and warrants further studies on the use and precautions of bone-modulating management in clonal blood disorders.

We provide novel data on the efficacy of putative and established therapies in patient-derived GEP-NEN primary cultures. Our standardized platform for personalized drug screening and risk assessment in GEP-NEN primary cultures enables prediction of individual tumor treatment response in this orphan disease.

P4, N=200, Recruiting, University Hospital, Toulouse | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Oct 2030 | Initiation date: Mar 2025 --> Oct 2025 | Trial primary completion date: Mar 2030 --> Oct 2030

P1, N=24, Recruiting, Emory University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P4, N=44, Recruiting, National Taiwan University Hospital